Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 2, 2020

3-Iodothyronamine and 3,5,3′-triiodo-L-thyronine reduce SIRT1 protein expression in the HepG2 cell line

Ginevra Sacripanti, Leonardo Lorenzini, Lavinia Bandini, Sabina Frascarelli, Riccardo Zucchi and Sandra Ghelardoni ORCID logo

Abstract

Background

3-Iodothyronamine (T1AM) is an endogenous messenger chemically related to thyroid hormone. Recent results indicate significant transcriptional effects of chronic T1AM administration involving the protein family of sirtuins, which regulate important metabolic pathways and tumor progression. Therefore, the aim of this work was to compare the effect of exogenous T1AM and 3,5,3′-triiodo-L-thyronine (T3) chronic treatment on mammalian sirtuin expression in hepatocellular carcinoma cells (HepG2) and in primary rat hepatocytes at micromolar concentrations.

Materials and methods

Sirtuin (SIRT) activity and expression were determined using a colorimetric assay and Western blot analysis, respectively, in cells treated for 24 h with 1–20 μM T1AM or T3. In addition, cell viability was evaluated by the MTTtest upon 24 h of treatment with 0.1–20 μM T1AM or T3.

Results

In HepG2, T1AM significantly reduced SIRT 1 (20 μM) and SIRT4 (10–20 μM) protein expression, while T3 strongly decreased the expression of SIRT1 (20 μM) and SIRT2 (any tested concentration). In primary rat hepatocytes, T3 decreased SIRT2 expression and cellular nicotinamide adenine dinucleotide (NAD) concentration, while on sirtuin activity it showed opposite effects, depending on the evaluated cell fraction. The extent of MTT staining was moderately but significantly reduced by T1AM, particularly in HepG2 cells, whereas T3 reduced cell viability only in the tumor cell line.

Conclusions

T1AM and T3 downregulated the expression of sirtuins, mainly SIRT1, in hepatocytes, albeit in different ways. Differences in mechanisms are only observational, and further investigations are required to highlight the potential role of T1AM and T3 in modulating sirtuin expression and, therefore, in regulating cell cycle or tumorigenesis.

Acknowledgment

The authors thank Prof. Aldo Paolicchi and Dr. Vanna Fierabacci for their technical support in primary cell culture preparation.

Author statement

  1. Research funding: Funding for this study was provided by the University of Pisa (549999_2017_GHELARDONI_ATENEO).

  2. Conflict of interest: The authors have no conflicting interests to declare.

  3. Informed consent: Not applicable.

  4. Ethical approval: Experimental procedures were approved by the ethical committee of the University of Pisa (protocol n.51814/2016).

References

[1] Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med. 2004;10:638–42.10.1038/nm1051Search in Google Scholar PubMed

[2] Snead AN, Santos MS, Seal RP, Miyakawa M, Edwards RH, Scanlan TS. Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem Biol. 2007;2:390–8.10.1021/cb700057bSearch in Google Scholar PubMed

[3] Venditti P, Napolitano G, Di Stefano L, Chiellini G, Zucchi R, Scanlan TS, et al. Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity. Mol Cell Endocrinol. 2011;341:55–62.10.1016/j.mce.2011.05.013Search in Google Scholar PubMed PubMed Central

[4] Saba A, Chiellini G, Frascarelli S, Marchini M, Ghelardoni S, Raffaelli A, et al. Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology. 2010;151:5063–73.10.1210/en.2010-0491Search in Google Scholar PubMed

[5] Roy G, Placzek E, Scanlan TS. ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation. J Biol Chem. 2012;287:1790–800.10.1074/jbc.M111.275552Search in Google Scholar PubMed PubMed Central

[6] Hoefig CS, Wuensch T, Rijntjes E, Lehmphul I, Daniel H, Schweizer U, et al. Biosynthesis of 3-iodothyronamine from T4 in murine intestinal tissue. Endocrinology. 2015;156:4356–64.10.1210/en.2014-1499Search in Google Scholar PubMed

[7] Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid. 2002;12:459–66.10.1089/105072502760143827Search in Google Scholar PubMed

[8] Chung IH, Chen CY, Lin YH, Chi HC, Huang YH, Tai PJ, et al. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget. 2015;6:15050–64.10.18632/oncotarget.3670Search in Google Scholar PubMed PubMed Central

[9] Ledda-Columbano GM, Perra A, Loi R, Shinozuka H, Columbano A. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. Cancer Res. 2000;60:603–9.Search in Google Scholar

[10] Liao CH, Yeh CT, Huang YH, Wu SM, Chi HC, Tsai MM, et al. Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology. 2012;55:910–20.10.1002/hep.24740Search in Google Scholar PubMed

[11] Braulke LJ, Klingenspor M, DeBarber M, Tobias SC, Grandy DK, Scanlan TS, et al. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. J Comp Physiol B. 2008;178:167–77.10.1007/s00360-007-0208-xSearch in Google Scholar PubMed

[12] Ghelardoni S, Chiellini G, Frascarelli S, Saba A, Zucchi R. Uptake and metabolic effects of 3-iodothyronamine in hepatocytes. J Endocrinol. 2014;221:101–10.10.1530/JOE-13-0311Search in Google Scholar

[13] Haviland J, Reiland H, Butz DE, Tonelli M, Porter WP, Zucchi R, et al. NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T1 AM treatment. Obesity. 2012;21:2538–44.10.1002/oby.20391Search in Google Scholar

[14] Assadi-Porter F, Reiland H, Sabatini M, Lorenzini L, Carnicelli V, Rogowski M, et al. Metabolic reprogramming by 3-iodothyronamine (T1AM): a new perspective to reverse obesity through co-regulation of sirtuin4 and 6 expression. Int J Mol Sci. 2018;19:E1535.10.3390/ijms19051535Search in Google Scholar

[15] Guarente L, Franklin H. Epstein lecture: sirtuins, aging, and medicine. N Engl J Med. 2011;364:2235–44.10.1056/NEJMra1100831Search in Google Scholar

[16] Suh JH, Sieglaff DH, Zhang A, Xia X, Cvoro A, Winnier GE, et al. SIRT1 is a direct coactivator of thyroid hormone receptor β1 with gene-specific actions. PLoS One. 2013;8:e70097.10.1371/journal.pone.0070097Search in Google Scholar

[17] Hashimoto K, Cohen RN, Yamada M, Markan KR, Monden T, Satoh T, et al. Cross-talk between thyroid hormone receptor and liver X receptor regulatory pathways is revealed in a thyroid hormone resistance mouse model. J Biol Chem. 2006;281:295–302.10.1074/jbc.M507877200Search in Google Scholar

[18] Cordeiro A, de Souza LL, Oliveira LS, Faustino LC, Santiago LA, Bloise FF, et al. Thyroid hormone regulation of Sirtuin 1 expression and implications to integrated responses in fasted mice. J Endocrinol. 2013;216:181–93.10.1530/JOE-12-0420Search in Google Scholar

[19] Paolicchi A, Tongiani R, Tonarelli P, Comporti M, Pompella A. Gamma-glutamyl transpeptidase-dependent lipid peroxidation in isolated hepatocytes and HepG2 hepatoma cells. Free Radic Biol Med. 1997;22:853–60.10.1016/S0891-5849(96)00422-4Search in Google Scholar

[20] Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.10.1016/0003-2697(76)90527-3Search in Google Scholar

[21] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983;65:55–63.10.1016/0022-1759(83)90303-4Search in Google Scholar

[22] Mei Z, Zhang X, Yi J, Huang J, He J, Tao Y. Sirtuins in metabolism, DNA repair and cancer. J Exp Clin Cancer Res. 2016;35:182.10.1186/s13046-016-0461-5Search in Google Scholar PubMed PubMed Central

[23] Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene. 2014;33:1609–20.10.1038/onc.2013.120Search in Google Scholar PubMed PubMed Central

[24] Chen J, Zhang B, Wong N, Lo AW, To KF, Chan AW, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011;71:4138–49.10.1158/0008-5472.CAN-10-4274Search in Google Scholar PubMed

[25] Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci. 2010;35:669–75.10.1016/j.tibs.2010.07.003Search in Google Scholar PubMed PubMed Central

[26] Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci. 2012;1271:10–9.10.1111/j.1749-6632.2012.06762.xSearch in Google Scholar PubMed PubMed Central

[27] Fang Y, Nicholl MB. Sirtuin1 in malignant transformation: friend or foe? Cancer Lett. 2011;306:10–4.10.1016/j.canlet.2011.02.019Search in Google Scholar PubMed

[28] Chen J, Chan AW, To KF, Chen W, Zhang Z, Ren J, et al. SIRT 2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3b/b-catenin signaling. Hepathology. 2013;57:2287–98.10.1002/hep.26278Search in Google Scholar PubMed

[29] Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006;66:4368–77.10.1158/0008-5472.CAN-05-3617Search in Google Scholar PubMed

[30] Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012;7:e45119.10.1371/journal.pone.0045119Search in Google Scholar PubMed PubMed Central

[31] Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007;282:6823–32.10.1074/jbc.M609554200Search in Google Scholar PubMed

[32] Mariotti V, Melissari E, Iofrida C, Righi M, Di Russo M, Donzelli R, et al. Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern. PLoS One. 2014;9:e106923.10.1371/journal.pone.0106923Search in Google Scholar PubMed PubMed Central

[33] Nasrin N, Wu X, Fortier E, Feng Y, Bare’ OC, Chen S, et al. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem. 2010;285:31995–2002.10.1074/jbc.M110.124164Search in Google Scholar PubMed PubMed Central

[34] Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, Pierce K, et al. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23:450–63.10.1016/j.ccr.2013.02.024Search in Google Scholar PubMed PubMed Central

[35] Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20:487–99.10.1016/j.ccr.2011.09.004Search in Google Scholar PubMed PubMed Central

Received: 2019-08-01
Accepted: 2019-12-13
Published Online: 2020-03-02

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Scroll Up Arrow